medigraphic.com
ISSN 0016-3813 (Print)

2004, Number 5

<< Back Next >>

Gac Med Mex 2004; 140 (5)

All-trans retinoic acid Syndrome. Case Report and a Review of the Literature.

Carrillo-Esper R, Carvajal-Ramos R, Contreras-Domínguez V, Hernández-Aguilar C, Romano-Estrada L, Melo-Martínez C

Language: Spanish
References: 50
Page: 547-552
PDF size: 548.61 Kb.


ABSTRACT

We described a patient with acute promyelocytic leukemia (APL) who developed all-trans retinoic acid syndrome (ATRAS) and reviewed the literature. ATRAS presents in patients with APL treated with all-trans retinoic acid (ATRA). It has an incidence from 5%–27% with mortality of 29%. It is secondary to ATRA effect on promyelocyte differentiation, which causes systemic inflammatory response syndrome, endothelium damage with increase in capillary permeability, microcirculation obstruction, and tissue infiltration. ATRAS clinical manifestations are fever, hypotension, respiratory, renal and hepatic insufficiency, lung infiltrates, pleural and pericardic efussion, and generalized edema. Treatment is based on ATRA suspension, support measures, and steroids.


REFERENCES

  1. Powell BL. Acute progranulocytic leukemia. Curr Opin Oncol 2001;13:8-13.

  2. Bennett J, Catovsky D, Daniel M, et al. Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 1985;103:626-629.

  3. Stone RM, Mayer RJ. The unique aspects of acute promyelocytic leukemia. J Clin Oncol 1990;8:1913-1921.

  4. Neame PB, Soamboonsrup P, Leber B, et al. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: characterization of additional microgranular variants. Am J Hematol 1997;56:131-142.

  5. Tallman MS, Hakimian D, Kwaan HC, et al. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leuk Lymphoma 1993;11:27-36.

  6. Mattson JC. Acute promyelocytic leukemia: from morphology to molecular lesions. Clin Lab Med 2000;20:83-103.

  7. Melnick A, Licht JD. Deconstructing a disease: RARa, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 1999;93:3167-3215.

  8. Mattei MG, Petkovich M, Mattei JF, et al. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet 1988;80:186-188.

  9. Wang ZG, Ruggero D, Ronchetti S, et al. PML is essential for multiple apoptoic pathways. Nat Genet 1998;20:266-272.

  10. Slack JL, Rusiniak ME. Current issues in the management of acute promyelocytic leukemia. Ann Hematol 2000;79:227-238.

  11. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997;337:1021-1028.

  12. Fenaux P, Le Deley MC, Castaigne S, et al. European APL 91 Group : Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-3249.

  13. Fenaux P, Chastang C, Chevret S, et al. European APL Group: A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood

  14. 1999;94:1192-1200.

  15. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with antracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARa-positive acute promyelocytic leukemia. Blood 1999;94:3015-3021.

  16. Mandelli F, Diverio D, Avvisati G, et al. Molecular remission in PML/RARapositive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997;90:1014-1021.

  17. Frankel SR, Eardley A, lauwers G, Weiss M, Warrell RP Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann Intern Med 1992;117:292-296.

  18. Jonathan KM. The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 1999;11:497-503.

  19. Zhang P, Wang SY, Hu LH, et al. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996;2:58-60.

  20. Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia: II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997;89:3354-3360.

  21. Kinjo K, Kizaki M, Muto A, et al. Arsenic trioxide (As203)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 2000;14:431-438.

  22. Frankel SR, Eardley A, Heller G, Berman E, et al. All-trans retinoic acid for acute promyelocytic leukemia. Ann Intern Med 1994;120:278-286.

  23. De Botton S, Dombret H, Sanz M, San Miguel J, et al. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic Leukemia. Blood 1998;8:2712-2718.

  24. Fenaux P, Le Deley MC, Castaigne S. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993;82:3241-3246.

  25. Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, et al. All-transretinoic acid for the treatment of newly diagnosed acute promyelocytic leucemia. Blood 1995;85:1202-1210.

  26. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000;95:90-95.

  27. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leucocytosis, and dose chemotherapy, PML-RARa isoform, and CD13 expression in patients with all-trans retinoic acid. Blood 1994;84:3843-3849.

  28. Asou N, Adachi K, Tamura J, Kanamaru A, et al. Analisis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with alltrans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group. J Clin Oncol 1998;16;78-85.

  29. Cortes JE, Kantarjian H, O’Brien S, Robertson LE, et al. All trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia. Cancer 1994;73:294-299.

  30. Seale J, Delva L, Renesto P, et al. All-trans retinoic acid rapidly decrease cathepsin G síntesis and mRNA expresión in acute promyelocytic leucemia. Leukemia 1996;10:95-101.

  31. Di Noto R, Schiavone EM, Ferrara F, Manzo C, et al. All-trans retinoic acid promotes a differential regulation of adhesion molecules on acute myeloid blast cells. Br J Haematol 1996;88:247-255.

  32. Di Noto R, Schiavone EM, Ferrara F, Manzo C, et al. Expression and ATRAdriven modulation of adhesion molecules in acute promyelocytic leukemia. Leukemia 1994;8(Suppl 2):S71-S76.

  33. Dubois C, Schlageter MH, de Gentile A, et al. Modulation of IL-8, IL-1b, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 1994;8:1750-1757.

  34. Marchetti M, Falanga A, Giovanelli S, Oldani E, et al. All-trans retinoic acid increases adhesion to endothelium of the human APML cell line NB4. Br J Haematol 1996;93:360-366.

  35. Larson RS, Brown DC, Sklar LA. Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB4 by utilization of LFA-1 and ICAM-2. Blood 1997;90:2747-2756.

  36. Dedhra S, Robertson K, Gray V. Induction of expression of the aVb1 and aVb3 integrin heterodimers during retinoic acid-induced neuronal differentiation of murine embryonal carcinoma cells. J Biol Chem 1991;266:21846-21851.

  37. Zhang A, Taron G, Turner DC. Expression of integrin a1b1 is regulated by nerve growth factor and dexamethasone in PC12 cells: Functional consequences for adhesion and neurite growth. J Biol Chem 1993;268:55-57.

  38. Castaigne S, Lefebvre P, Chomienne C, et al. Efectiveness and pharmacokinetics of low-dose all-trans retinoic acid (25 mg/m²) in acute promyelocytic leukemia. Blood 1993;82:3560-3563.

  39. Chen GQ, Shen ZX, Wu F, et al. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 1996;10:825-828.

  40. Miller VA, Rigas JR, Benedetti FM, et al. Initial clinical trials of the retinoid receptor panagonist 9-cis retinoic acid. Clin Cancer Res 1996;2:471-475.

  41. Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood 1997;90:967-973.

  42. Kakkar N. ATRA syndrome with extensive organ infiltration. Am J Hematol 2002;71:62-64.

  43. Fenaux P, De Botton S. Retinoic acid syndrome. Recognition, prevention and management. Drug Saf 1998;18:273-279.

  44. Gendrel D, Bohuon C. Procalcitonin as a marker of bacterial infection. Pediatr Infect Dis J 2000;19:679-688.

  45. Boschini P. Síndrome del ácido retinóico. Patología de Urgencia 2001;9:16-22.

  46. Tommasino C, et al. Retinoic acid sindrome, severe respiratory insufficiency treated with CPAP. Minerva Anestesiol 2000;66:555-559.

  47. Cogliati A, Conti G, Tritapepe L, Canneti A, et al. Noninvasive ventilation in the treatment of acute respiratory failure induced by all-trans retinoic acid (retinoic acid syndrome) in children with acute promyelocytic leukemia. Pediatr Crit Care Med 2002;3:70-73.

  48. Nagafuji K, Eto T, Tokunaga Y, Hayashi S, et al. Retinoic acid syndrome during the treatment of acute myelomonocytic leukaemia with all-transretinoic acid and low-dose cytosine arabinósido. Br J Haematol;100:610-611.

  49. Miyoshi TK. Acute promyelocytic leukemia accompanied by retinoic acid syndrome with complications of acute myocardial infarction and cerebral infarction during treatment with all-trans retinoic acid. Rinsho Ketsueki 2002;43:954-959.

  50. Hwang WL, Gau JP, Chen MC, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: Succesful control of hyperleucocytosis and leucostasis syndrome with leukaphereses and hydroxyurea. Am J Hematol 1993;43:323-324.




2020     |     www.medigraphic.com